Literature DB >> 16189296

The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide.

Roberto R Rosato1, Sonia C Maggio, Jorge A Almenara, Shawn G Payne, Peter Atadja, Sarah Spiegel, Paul Dent, Steven Grant.   

Abstract

Determinants of differentiation and apoptosis induction by the novel histone deacetylase inhibitor (HDACI) LAQ824 were examined in human leukemia cells (U937 and Jurkat). Exposure of U937 cells to a low concentration of LAQ824 (30 nM) resulted in a delayed (2 h) increase in reactive oxygen species (ROS), induction of p21(WAF1/CIP1), pRb dephosphorylation, growth arrest of cells in G(0)/G(1) phase, and differentiation. On the other hand, exposure of cells to a higher concentration of LAQ824 (75 nM) resulted in the early (30 min) generation of ROS, arrest of cells in G(2)/M phase, down-regulation of XIAP (at the transcriptional level) and Mcl-1 (through a caspase-mediated process), the acid sphingomyelinase-dependent generation of ceramide, and profound mitochondrial injury, caspase activation, and apoptosis. LAQ824-induced lethality in U937 cells did not involve the extrinsic apoptotic pathway, nor was it associated with death receptor up-regulation; instead, it was markedly inhibited by ectopic expression of Bcl-2, Bcl-x(L), XIAP, and Mcl-1. The free radical scavenger N-acetyl cysteine blocked LAQ824-mediated ROS generation, mitochondrial injury, Mcl-1 down-regulation, ceramide generation, and apoptosis, suggesting a primary role for oxidative injury in LAQ824 lethality. Together, these findings indicate that LAQ824-induced lethality represents a multifactorial process in which LAQ824-mediated ROS generation is necessary but not sufficient to induce apoptosis, and that the degree of XIAP and Mcl-1 down-regulation and ceramide generation determines whether this agent engages a maturation rather than an apoptotic program.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16189296     DOI: 10.1124/mol.105.017145

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  34 in total

1.  The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells.

Authors:  Ke Long Jin; Jeong-Yeol Park; Eun Joo Noh; Kwang Lae Hoe; Joo Hak Lee; Jong-Hyeok Kim; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

2.  Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.

Authors:  Susan E Bates; Zhirong Zhan; Kenneth Steadman; Tomasz Obrzut; Victoria Luchenko; Robin Frye; Robert W Robey; Maria Turner; Erin R Gardner; William D Figg; Seth M Steinberg; Alex Ling; Tito Fojo; Kin Wah To; Richard L Piekarz
Journal:  Br J Haematol       Date:  2009-10-28       Impact factor: 6.998

3.  SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.

Authors:  Qiangui Bu; Lijing Cui; Juan Li; Xin Du; Waiyi Zou; Ke Ding; Jingxuan Pan
Journal:  Cancer Biol Ther       Date:  2014-04-23       Impact factor: 4.742

Review 4.  Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.

Authors:  Paul A Marks
Journal:  Biochim Biophys Acta       Date:  2010-06-08

Review 5.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Authors:  Prithviraj Bose; Yun Dai; Steven Grant
Journal:  Pharmacol Ther       Date:  2014-04-24       Impact factor: 12.310

Review 6.  Cancer treatment strategies targeting sphingolipid metabolism.

Authors:  Babak Oskouian; Julie D Saba
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 7.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

8.  Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.

Authors:  Roberto R Rosato; Jorge A Almenara; Sonia C Maggio; Stefanie Coe; Peter Atadja; Paul Dent; Steven Grant
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

9.  Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer.

Authors:  Yuanqing Wu; Bingliang Fang; Xiulan Q Yang; Li Wang; Dongning Chen; Victor Krasnykh; Bing Z Carter; Jeffrey S Morris; Imad Shureiqi
Journal:  Mol Ther       Date:  2008-03-18       Impact factor: 11.454

Review 10.  Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.

Authors:  Giuseppe Leone; Francesco D'Alò; Giuseppe Zardo; Maria Teresa Voso; Clara Nervi
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.